Compare ARVN & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | IHRT |
|---|---|---|
| Founded | 2015 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 589.5M |
| IPO Year | 2018 | 2019 |
| Metric | ARVN | IHRT |
|---|---|---|
| Price | $8.27 | $2.33 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 19 | 2 |
| Target Price | ★ $15.05 | $4.25 |
| AVG Volume (30 Days) | ★ 711.6K | 403.3K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | 54.19 |
| EPS | ★ 1.70 | N/A |
| Revenue | $262,600,000.00 | ★ $3,864,991,000.00 |
| Revenue This Year | N/A | $9.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.89 | ★ N/A |
| Revenue Growth | N/A | ★ 0.27 |
| 52 Week Low | $6.97 | $2.43 |
| 52 Week High | $14.22 | $6.56 |
| Indicator | ARVN | IHRT |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 28.45 |
| Support Level | $7.90 | N/A |
| Resistance Level | $8.40 | $2.90 |
| Average True Range (ATR) | 0.32 | 0.13 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 11.88 | 1.75 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.